1. Home
  2. VBIX vs VYNE Comparison

VBIX vs VYNE Comparison

Compare VBIX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBIX
  • VYNE
  • Stock Information
  • Founded
  • VBIX N/A
  • VYNE 2003
  • Country
  • VBIX Israel
  • VYNE United States
  • Employees
  • VBIX N/A
  • VYNE N/A
  • Industry
  • VBIX Computer Software: Prepackaged Software
  • VYNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • VBIX Technology
  • VYNE Health Care
  • Exchange
  • VBIX Nasdaq
  • VYNE Nasdaq
  • Market Cap
  • VBIX 44.0M
  • VYNE 35.7M
  • IPO Year
  • VBIX N/A
  • VYNE 2018
  • Fundamental
  • Price
  • VBIX $4.49
  • VYNE $0.90
  • Analyst Decision
  • VBIX
  • VYNE Strong Buy
  • Analyst Count
  • VBIX 0
  • VYNE 2
  • Target Price
  • VBIX N/A
  • VYNE $6.25
  • AVG Volume (30 Days)
  • VBIX 43.4K
  • VYNE 349.2K
  • Earning Date
  • VBIX 08-14-2025
  • VYNE 05-08-2025
  • Dividend Yield
  • VBIX N/A
  • VYNE N/A
  • EPS Growth
  • VBIX N/A
  • VYNE N/A
  • EPS
  • VBIX N/A
  • VYNE N/A
  • Revenue
  • VBIX $19,672,000.00
  • VYNE $605,000.00
  • Revenue This Year
  • VBIX N/A
  • VYNE N/A
  • Revenue Next Year
  • VBIX N/A
  • VYNE N/A
  • P/E Ratio
  • VBIX N/A
  • VYNE N/A
  • Revenue Growth
  • VBIX N/A
  • VYNE 43.03
  • 52 Week Low
  • VBIX $0.18
  • VYNE $0.88
  • 52 Week High
  • VBIX $12.00
  • VYNE $4.30
  • Technical
  • Relative Strength Index (RSI)
  • VBIX N/A
  • VYNE 28.36
  • Support Level
  • VBIX N/A
  • VYNE $0.95
  • Resistance Level
  • VBIX N/A
  • VYNE $1.04
  • Average True Range (ATR)
  • VBIX 0.00
  • VYNE 0.06
  • MACD
  • VBIX 0.00
  • VYNE 0.01
  • Stochastic Oscillator
  • VBIX 0.00
  • VYNE 9.24

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Share on Social Networks: